XML 52 R40.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Data - Revenues by Geographic Areas (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 5,509 | $ 4,990 | $ 15,949 | $ 14,741
Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,927 | 2,558 | 8,302 | 7,237
Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,254 | 1,260 | 3,798 | 3,852
Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,328 | 1,240 | 3,849 | 3,720
Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 0 | (67) | 0 | (67)
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 3,181 | 2,891 | 9,369 | 8,546
United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,743 | 1,508 | 5,012 | 4,297
United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 539 | 546 | 1,717 | 1,712
United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 898 | 844 | 2,640 | 2,543
United States | Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 0 | (6) | 0 | (6)
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,328 | 2,098 | 6,581 | 6,195
International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,184 | 1,050 | 3,290 | 2,940
International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 714 | 714 | 2,081 | 2,139
International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 430 | 396 | 1,209 | 1,177
International | Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 0 | (62) | 0 | (62)
Medication Delivery Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,132 | 1,123 | 3,373 | 3,282
Medication Delivery Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 680 | 670 | 2,060 | 1,971
Medication Delivery Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 452 | 453 | 1,313 | 1,310
Medication Management Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 888 | 840 | 2,500 | 2,359
Medication Management Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 709 | 680 | 2,030 | 1,883
Medication Management Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 179 | 160 | 470 | 475
Pharmaceutical Systems | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 629 | 594 | 1,622 | 1,596
Pharmaceutical Systems | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 178 | 158 | 431 | 442
Pharmaceutical Systems | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 451 | 437 | 1,191 | 1,154
Advanced Patient Monitoring | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 278 | 0 | 806 | 0
Advanced Patient Monitoring | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 176 | 0 | 490 | 0
Advanced Patient Monitoring | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 102 | 0 | 317 | 0
Specimen Management | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 470 | 467 | 1,387 | 1,372
Specimen Management | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 240 | 239 | 721 | 708
Specimen Management | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 230 | 228 | 667 | 664
Diagnostic Solutions | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 425 | 429 | 1,340 | 1,365
Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 154 | 167 | 556 | 578
Diagnostic Solutions | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 271 | 263 | 783 | 787
Biosciences | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 358 | 363 | 1,071 | 1,115
Biosciences | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 145 | 141 | 440 | 426
Biosciences | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 213 | 222 | 631 | 689
Surgery | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 395 | 376 | 1,173 | 1,124
Surgery | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 294 | 283 | 885 | 851
Surgery | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 101 | 93 | 288 | 273
Peripheral Intervention | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 512 | 488 | 1,466 | 1,431
Peripheral Intervention | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 271 | 263 | 793 | 762
Peripheral Intervention | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 241 | 225 | 673 | 669
Urology and Critical Care | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 422 | 375 | 1,211 | 1,165
Urology and Critical Care | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 334 | 297 | 962 | 930
Urology and Critical Care | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 88 | $ 78 | $ 249 | $ 234

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_AdvancedPatientMonitoringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SpecimenManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_DiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |